Home
GSC Advanced Research and Reviews
Peer-reviewed | Multidisciplinary Journal | Impact factor 8.3 | ISSN: 2582-4597 | Crossref DOI

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Reviewer Panel
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

CD23 IN PARKINSON’S DISEASE: RATIONALE AND CHALLENGES FOR EXPLORING PREFORMED ANTI-IGE:IGE COMPLEXES

Breadcrumb

  • Home
  • CD23 IN PARKINSON’S DISEASE: RATIONALE AND CHALLENGES FOR EXPLORING PREFORMED ANTI-IGE:IGE COMPLEXES

Michael John Dochniak *

Minnesota, USA.
* Corresponding Author

Review Article

GSC Advanced Research and Reviews, 2026, 29(01), 265–269

Article DOI: 10.30574/gscarr.2026.29.1.0285

DOI url: https://doi.org/10.30574/gscarr.2026.29.1.0285

Received on 12 September 2026; revised on 18 October 2026; accepted on 20 October 2026

Parkinson’s disease (PD) is a progressive neurodegenerative disorder for which available treatments are primarily symptomatic. Neuroimmune changes are implicated in PD, and experimental work has reported CD23 (FcεRII) expression in glial cells and CD23-associated inflammatory mediator production in vitro. These findings provide a rationale for investigating CD23, but they do not establish that CD23 drives disease progression or that its modulation is therapeutic. This hypothesis-generating review considers whether a preformed anti-IgE antibody–IgE complex, such as UB-221 (also referred to as CUE-221), could alter CD23-associated signaling in PD. The proposed effects on glia, NOS2, and neuronal injury remain untested, as does the complex's ability to reach relevant brain compartments. Potential delivery approaches—including receptor-mediated transport and focused ultrasound—are discussed as research options rather than established solutions. Preclinical studies should first determine target expression, complex behavior and safety, functional effects in relevant PD models, and brain exposure. CD23-directed immunomodulation is therefore a speculative research hypothesis, not an established disease-modifying strategy.

Parkinson’s Disease, Neuroinflammation, Immunotherapy, CD23, Preformed CUE22: Ige, B-Cell Modulation

https://gscarr.gsconlinepress.com/sites/default/files/fulltext_pdf/GSCARR-2026-…

Preview Article PDF

Michael John Dochniak. CD23 IN PARKINSON’S DISEASE: RATIONALE AND CHALLENGES FOR EXPLORING PREFORMED ANTI-IGE:IGE COMPLEXES. GSC Advanced Research and Reviews, 2026, 29(01), 265–269. Article DOI: https://doi.org/10.30574/gscarr.2026.29.1.0285.

Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s). The journal, editors, reviewers, and publisher disclaim any responsibility or liability for the content, including accuracy, completeness, or any consequences arising from its use.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content

Copyright © 2026 GSC Advanced Research and Reviews - All rights reserved

Developed & Designed by VS Infosolution